202 related articles for article (PubMed ID: 20586711)
41. [EGFR testing: state of organizations in France in 2010].
Nowak F
Rev Pneumol Clin; 2011 Jun; 67 Suppl 1():S3-4. PubMed ID: 21777764
[No Abstract] [Full Text] [Related]
42. Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies.
Joshi VA; Kucherlapati R
Pharmacogenomics; 2007 Sep; 8(9):1211-20. PubMed ID: 17924836
[TBL] [Abstract][Full Text] [Related]
43. [Current status of the study of the mechanism of epidermal growth factor receptor targeting drug therapy and their related markers].
Wang Y; Xu JM; Song ST
Zhonghua Zhong Liu Za Zhi; 2005 Sep; 27(9):573-6. PubMed ID: 16438862
[No Abstract] [Full Text] [Related]
44. Targeted lung cancer therapies.
Farmer G
Nat Rev Drug Discov; 2004 Jul; 3(7):547-8. PubMed ID: 15272497
[No Abstract] [Full Text] [Related]
45. Cetuximab: potential role as first-line treatment for advanced non-small cell lung cancer.
Pirker R
Clin Adv Hematol Oncol; 2008 Oct; 6(10):735-6. PubMed ID: 18997663
[No Abstract] [Full Text] [Related]
46. Unlocking the biological clues of lung cancer.
Hanna N
J Thorac Oncol; 2008 Aug; 3(8):809-10. PubMed ID: 18670296
[No Abstract] [Full Text] [Related]
47. EGFR testing in lung cancer is ready for prime time.
Hirsch FR; Bunn PA
Lancet Oncol; 2009 May; 10(5):432-3. PubMed ID: 19410185
[No Abstract] [Full Text] [Related]
48. Comprehensive symptom management in patients with advanced-stage non-small-cell lung cancer.
Temel JS; Pirl WF; Lynch TJ
Clin Lung Cancer; 2006 Jan; 7(4):241-9. PubMed ID: 16512977
[TBL] [Abstract][Full Text] [Related]
49. The roles of epidermal growth factor receptor (EGFR) inhibitors in the management of lung cancer.
Al Olayan A; Al Hussaini H; Jazieh AR
J Infect Public Health; 2012 Dec; 5 Suppl 1():S50-60. PubMed ID: 23244189
[TBL] [Abstract][Full Text] [Related]
50. Personalized medicine for non-small-cell lung cancer.
Kucherlapati R
Oncology (Williston Park); 2010 Apr; 24(5):399-400. PubMed ID: 20480736
[No Abstract] [Full Text] [Related]
51. The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation.
Langer CJ
J Clin Oncol; 2009 Mar; 27(9):1350-4. PubMed ID: 19224840
[No Abstract] [Full Text] [Related]
52. Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer.
Sacco PC; Maione P; Rossi A; Sgambato A; Casaluce F; Palazzolo G; Gridelli C
Expert Rev Respir Med; 2015 Jun; 9(3):245-54. PubMed ID: 25797462
[TBL] [Abstract][Full Text] [Related]
53. [Application strategies of the third-generation EGFR-TKI in the context of precision medicine].
Zhao J; Zhang SJ; Zhou CC
Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):86-89. PubMed ID: 28219200
[TBL] [Abstract][Full Text] [Related]
54. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors.
Wozniak AJ
J Thorac Oncol; 2009 Nov; 4(11 Suppl 3):S1084-5. PubMed ID: 19861927
[No Abstract] [Full Text] [Related]
55. More than just an oncogene translocation and a kinase inhibitor: Kevin's story.
Costa DB
J Clin Oncol; 2012 Jan; 30(1):110-2. PubMed ID: 22067391
[No Abstract] [Full Text] [Related]
56. Advanced non-small-cell lung cancer: new data, therapy choices, and challenging decisions.
Sandler AB
Oncology (Williston Park); 2006 May; 20(6):626-8. PubMed ID: 16773846
[No Abstract] [Full Text] [Related]
57. Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Van Sebille YZ; Gibson RJ; Wardill HR; Bowen JM
Curr Opin Support Palliat Care; 2016 Jun; 10(2):152-6. PubMed ID: 27035390
[No Abstract] [Full Text] [Related]
58. The diverse diversity.
Mok TS; Lam KC
J Thorac Oncol; 2011 May; 6(5):842-3. PubMed ID: 21623264
[No Abstract] [Full Text] [Related]
59. Paradoxical clinical effects of epidermal growth factor receptor-tyrosine kinase inhibitors for acute myelogenous leukemia.
Hotta K; Kiura K; Takigawa N; Matsuo K; Tabata M; Fujiwara Y; Tanimoto M
J Clin Oncol; 2008 Dec; 26(35):5826-7; author reply 5827. PubMed ID: 19001344
[No Abstract] [Full Text] [Related]
60. Will FLEX allow us flexibility in the therapy of advanced non-small-cell lung cancer? Insights from the 2008 American Society of Clinical Oncology Meeting.
Langer CJ
Clin Lung Cancer; 2008 Sep; 9(5):249-51. PubMed ID: 18824445
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
